HIGHLIGHTS OF THE SOCIETY FOR MEDICINES RESEARCH SYMPOSIUM, HELD ON SEPTEMBER 22, 2010, LONDON, UK

摘要

On September 22, 2010, the Society for Medicines Research (SMR) held a 1-day meeting entitled Epigenetics. The first generation of epigenetic-modifying drugs (histone deacetylase inhibitors and DNA methyltrans-ferase inhibitors) have now reached the marketplace and are rapidly proving to be useful agents fora range of oncology indications. An explosion in the amount of research being carried out in this field is under way, with a plethora of new histone- and DNA-modifying drug targets being pursued for a range of therapeutic indications, such as cancer, inflammatory disorders and metabolic diseases. This SMR symposium brought together a panel of international speakers across the breadth of research and development in the field of epigenetic drug discovery, to present and discuss new advances and results from early research to clinical data. Topics included the fundamental biology of epigenetics, therapeutic opportunities and approaches, first-generation epigenetic drug case histories in oncology and the next generation of epigenetic drugs.